Halozyme Reports Record 2025 Revenue, Reiterates Strong 2026 Guidance with Significant Growth
HALO sits 59% above its 52-week low of $47.5.
Summary
Halozyme Therapeutics reported record full-year 2025 revenue of $1.4 billion, driven by its ENHANZE business, and reiterated its robust 2026 financial guidance projecting substantial growth in revenue, EBITDA, and non-GAAP EPS.
Key Events · Earnings and Guidance · HALO
-
Record 2025 Revenue Achieved
Halozyme reported record full-year 2025 total revenue of $1.4 billion, a 38% increase year-over-year, primarily driven by continued growth in its ENHANZE business and partner product sales.
-
Strong 2026 Guidance Reiterated
The company reiterated its robust 2026 financial guidance, projecting total revenue of $1.71 billion to $1.81 billion (22-30% YOY growth) and non-GAAP diluted EPS of $7.75 to $8.25 (87-99% YOY growth). This follows the significant guidance raise on January 28, 2026.
-
Acquisition Impact on 2025 Earnings
Full-year 2025 GAAP diluted EPS of $2.56 and Non-GAAP diluted EPS of $4.15 were negatively impacted by a significant $284.9 million acquired in-process research and development (IPR&D) expense related to the Surf Bio acquisition, leading to a net loss in Q4 2025.
-
Strategic Portfolio Expansion
Halozyme completed the acquisitions of Elektrofi's Hypercon™ Technology and Surf Bio's hyperconcentration technology in late 2025, expanding its drug delivery technology portfolio to extend long-term royalty opportunities into the mid-2040s.
Analysis · HALO · Life Sciences
Halozyme Therapeutics delivered strong full-year 2025 financial results, achieving record total revenue of $1.4 billion, a 38% increase year-over-year, primarily fueled by its ENHANZE business and partner product sales. While GAAP and Non-GAAP diluted EPS for 2025 saw a decline due to a significant $284.9 million acquired in-process research and development (IPR&D) expense related to the Surf Bio acquisition, the underlying business performance remains robust. Crucially, the company reiterated its previously strong 2026 financial guidance, projecting total revenue growth of 22% to 30% and non-GAAP diluted EPS growth of 87% to 99%. This reiteration, following the initial guidance raise on January 28, 2026, reinforces investor confidence in the company's future growth trajectory and the long-term value of its expanded drug delivery technology portfolio. The substantial investment in acquisitions like Elektrofi and Surf Bio, while impacting short-term profitability, is aimed at diversifying and extending long-term royalty opportunities.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HALO was trading at $75.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $47.50 to $82.22. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.